Chronic migraine: diagnosis and treatment

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Chronic migraine (CM) is a specific form of migraine characterized by headache frequency exceeding 15 days per month, with at least 8 headache days being migrainous. The prevalence of CM in the general population ranges from 1.4 to 2.3%, reaching 6.8% in Russia.

CM significantly impairs patients’ ability to work and their quality of life, causes significant economic losses, and poses a serious problem for both patients and the national healthcare system.

This article presents current literature data reflecting modern understanding of the diagnosis and differential diagnosis of CM, as well as factors that contribute to its chronicity, and discusses current therapeutic approaches. According to the 2024 International Headache Society (IHS) guidelines, migraine-specific (targeted) medications are recommended as the primary treatment for migraine and CM. If necessary, they can be combined with other non-specific oral medications recommended for the treatment of migraine and comorbid conditions due to their different mechanisms of action.

Using the CGRP mAb erenumab, which blocks the CGRP receptor on the postsynaptic membrane and is one of the most effective and safe migraine prophylactic agents, it has been shown to halve the number of migraine days per month after just 3 months of therapy.

全文:

受限制的访问

作者简介

E. Filatova

I.M. Sechenov First Moscow State Medical University (Sechenov University); Alexander Vein Headache and Autonomic Disorders Clinic

编辑信件的主要联系方式.
Email: eg-filatova@mail.ru

Dr. Sci. (Med.), Professor of the Department of Nervous System Diseases, Institute of Postgraduate Education

俄罗斯联邦, Moscow; Moscow

参考

  1. Rasmussen B.K., Jensen R., Schroll M., Olesen J. Epidemiology of headache in a general population – a prevalence study. J Clin Epidemiol. 1991;44:1147–1157.
  2. Ayzenberg I., Katsarava Z., Sborowski A. et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012;32(5):373–381.
  3. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. https://dx.doi.org/10.1016/S0140-6736(17)32154-2
  4. Lipton R.B., Buse D.C., Saiers J., et al. Frequency and burden of headache-related nausea: Results from the AMPP study. Headache. 2013;53:93–103.
  5. Lipton R.B., Fanning K.M., Buse D.C., et al. Identifying natural subgroups of migraine based on comorbidity and concomitant condition profiles: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2018;58(7):933–947.
  6. Артеменко А.Р., Куренков А.Л., Беломестова К.В. Классификация, диагностика и лечение хронической мигрени: обзор новых данных. Журнал неврологии и психиатрии им. Корсакова. 2013;11:91–96. [Artemenko AR, Kurenkov AL, Belomestova KV. Classification, diagnosis and treatment of chronic migraine: review of new data. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(11):91–96. (In Russ.)].
  7. Scher A.I., Stewart W.F., Ricci J.A., Lipton R.B. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106 (2003) 81–89. https://dx.doi.org/10.1016/S0304-3959(03)00293-8
  8. Katsarava Z., Schneeweiss S., Kurth T., et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62:788–790.
  9. Louter M.A., Bosker J.E., van Oosterhout W.P., et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136:3489–3496.
  10. The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018;38(1):1–211.
  11. Burstein R., Noseda R., Borsook D.. Migraine: Multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619–6629.
  12. Dodick D.W. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018;58 Suppl 1:4–16. https://dx.doi.org/10.1111/head.13300
  13. Burch R.C., Buse D.C., Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. NeurolClin. 2019;37(4):631–649. https://dx.doi.org/10.1016/j.ncl.2019.06.001
  14. Buse D.C., Manack A., Serrano D., et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428–432.
  15. Артеменко А.Р., Куренков А.Л. Хроническая мигрень. М.: ИД « ФББ-пресс», 2012, 488 с. [Artemenko A.R., Kurenkov A.L. Chronic migraine. Moscow: ID «FBB-press», 2012, 488 p.
  16. Азимова Ю.Э., Амелин А.В., Алферова В.В. и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1 3):4–36. [Azimova Yu.E., Amelin A.V., Alferova V.V., et al. Clinical guidelines «Migraine». S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1–3):4–36. (In Russ.)]. https://dx.doi.org/10.17116/jnevro20221220134
  17. Puledda F., et al. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia. 2024 Sep;44(9):3331024241269735.
  18. Tepper S., Ashina M., Reuter U., et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434. https://dx.doi.org/10.1016/S1474-4422(17)30083-2
  19. Barbanti P. et al., Three year treatment with anti CGRP monoclonal antibodies modifes migraine course: the prospective, multicenter I GRAINE study. J Neurol. 2025;272:170. https://doi.org/10.1007/s00415-025-12911-w

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure 1. Probability of migraine chronification depending on baseline headache frequency

下载 (77KB)
索引源数据
3. Figure 2. Probability of migraine chronification with varying pain relief efficacy

下载 (84KB)
索引源数据
4. Figure 3. Results after 3 months of treatment with erenumab

下载 (115KB)
索引源数据

版权所有 © Bionika Media, 2025